EUCTR2007-003698-13-GB进行中（未招募）1 期
A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic lupus erythematosus (SLE) - Atacicept in generalised SLE Phase II/III
Merck Serono S.A. Geneva. An affiliate of Merck KGaA, Darmstadt, Germany0 个研究点目标入组 0 人开始时间: 2007年12月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Diagnosis of SLE satisfying at least 4 out of the 11 ACR criteria at the time of diagnosis, with a disease duration of at least six months.
- •2. Active SLE with at least one BILAG A or B score at initial screening (excluding a single B due to haematological values) requiring a change in the dose of corticosteroids.
- •3. Positive antinuclear antibody (ANA) test results (HEp-2 ANA =1:80 and/or anti dsDNA =30 IU/mL) (subjects will be tested at screening).
- •4. Male or female =16 years of age.
- •5. Written informed consent, given before any study-related procedure. Subjects must have read and understood the Informed Consent Form, must fully understand the requirements of the study and must be willing to comply with all study visits and assessments. For subjects under the age of legal majority (according to local law), the subject and a legal guardian must read and sign the informed consent.
- •6. Female subjects must be willing to avoid pregnancy by using an adequate method of contraception for 4 weeks prior to Study Day 1, during the trial and 24 weeks after the last dose of study medication. This requirement does not apply to surgically sterile subjects or to subjects who are post-menopausal for at least 2 years. Adequate contraception is defined as two barrier methods, or one barrier method with a spermicide, or an intrauterine device or use of a female hormonal contraceptive.
- •7. Women of childbearing potential must have a negative serum pregnancy test at initial screening and at the end of screening before dosing. For the purpose of this study, women of childbearing potential are defined as all female subjects after puberty unless they are post-menopausal for at least 2 years or surgically sterile.
- •In addition, to be eligible for inclusion into this trial, subjects must fulfil the following criteria at the end of the initial flare treatment period:
- •8. Improvement of the qualifying BILAG A or B flare to BILAG C or D within 10 weeks after commencing steroid treatment.
- •9. Use of an appropriate steroid regimen for the qualifying flare during the screening period, with stability of the dose at 7.5 mg of prednisone or equivalent for 2 weeks after improvement to BILAG C or D.
- •10. No other new BILAG A or B at an assessment performed following confirmation of stable steroid dose.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that constitutes a risk or a contraindication for participation to the study in the opinion of the Investigator or that could interfere with study objectives, conduct or evaluation.
- •2. Active moderate to severe glomerulonephritis
- •3. Active central nervous system SLE deemed to be severe or progressive and/or associated with significant cognitive impairment leading to inability to provide informed consent and/or comply with the protocol.
- •4. Comorbidities requiring systemic corticosteroid therapy (such as asthma or inflammatory bowel disease) and/or preventing engagement in study conduct.
- •5. Any history of treatment with rituximab, abatacept or belimumab.
- •6. Introduction of azathioprine, hydroxychloroquine, chloroquine, or methotrexate within 2 months before initial screening or increase in the dose regimen of any of these medications within 2 months before initial screening.
- •7. Initiation of any immunosuppressive drug within 3 months before initial screening.
- •8. Participation in any interventional clinical trial within the last 28 days or within 5 half-lives of the investigated compound (whichever is longer) before initial screening.
- •9. Treatment with cyclophosphamide mycophenolate mofetil or a calcineurin inhibitor within 3 months before initial screening.
- •10. Treatment with leflunomide, 6-mercaptopurine or thalidomide within 3 months before initial screening.
- •11. Active infection with herpes zoster or Epstein-Barr virus at initial screening.
- •12. Positive HIV serology (subjects will be tested at screening).
- •13. Positive hepatitis B surface antigen (HBsAg) or hepatitis C serology (subjects will be tested at screening).
- •14. History or presence of tuberculosis infection without documentation of adequate treatment, or treatment that occurred in the past year. Subjects should be evaluated and screened for tuberculosis according to national or local recommendations.
- •15. Known active clinically significant acute or chronic infection, or any major episode of infection requiring hospitalisation or treatment with parenteral anti-infectives within 4 weeks of baseline or completion of oral anti-infectives within 2 weeks prior to screening.
- •16. Diagnosis or family history of Creutzfeldt-Jakob disease (CJD).
- •17. History or presence of uncontrolled or New York Heart Association (NYHA) class 3 or 4 congestive heart failure.
- •18. History of cancer, except for adequately treated basal cell carcinoma of the skin, cervical dysplasia or carcinoma in situ of the skin or the cervix.
- •19. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (AP) level > 2.5 x ULN, or total bilirubin > 1.5 x ULN.
- •20. Clinically significant abnormality in any haematological test (e.g. haemoglobin < 5.5 mmol/L, WBC < 2.5 x 10^9/L, platelets < 75 x 10^9/L) unless attributable to active SLE.
- •21. Serum immunoglobulin G below 6 g/L.
- •22. Clinically significant abnormality on chest X-ray performed within 3 months of initial screening or on ECGs performed at initial screen
研究者
相似试验
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, multi national, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT), starting 2 months before the grass pollen season, administered as allergen based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis (with or without asthma)Grass pollen allergic rhinoconjunctivitisMedDRA version: 9.1Level: LLTClassification code 10039085Term: Rhinitis allergicMedDRA version: 9.1Level: PTClassification code 10039085Term: Rhinitis allergicEUCTR2008-003906-32-CZStallergenes S.A.336
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy - A Phase II dose-finding study of atacicept in RAMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-004140-23-PTMerck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany240
进行中（未招募）
1 期
A clinical study to assess the long-term efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosison-alcoholic Steatohepatitis (NASH)MedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2020-004986-38-HUInventiva S.A.1,200
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multicentre trial to access the safety and efficacy of pre-treatment with DF01 during late pregnancy in reducing prolonged labour.Pre-treatment during late pregnancy to reduce prolonged labour.EUCTR2006-005839-20-SEDilafor AB
进行中（未招募）
不适用
A single-dose study to investigate the effects of 3 different doses of inhaled AZD2115 in COPD patientsAZD2115 is being developed to treat chronic obstructive pulmonary disease (COPD).MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-004641-41-PLAstraZeneca AB36